FDA Approves Bysanti (Milsaperidone) for Schizophrenia & Bipolar I Disorder

The FDA has approved Bysanti (milsaperidone) — a new chemical entity for: ✔️ Schizophrenia (adults) ✔️ Acute manic or mixed episodes in Bipolar I Disorder (adults) But what makes this approval unique? Bysanti was approved using a bioequivalence bridging pathway to iloperidone (Fanapt) — allowing the FDA to leverage over 100,000+ patient-years of safety data. In this 30-minute deep dive, I break down: 🔬 The regulatory pathway (bioequivalence strategy explained) 🧠 Mechanism of action and dual-active metabolite system 📊 Receptor binding comparison vs risperidone, olanzapine, quetiapine & aripiprazole ⚖️ Alpha-1 adrenergic dominance — clinical implications 📉 Minimal H1 & M1 activity (metabolic and anticholinergic profile) 💊 Dosing considerations and titration pearls ⚠️ Orthostasis, QT prolongation & safety considerations 📍 Where Bysanti may fit in real-world practice Who Should Watch This? • Psychiatrists • Psychiatry residents • Psychiatric NPs & PAs • Primary care physicians • Pharmacists • Medical students Join Psychiatry Education Forum Academy: If you want structured, clinically relevant psychiatry education designed for busy professionals: 👉 https://psychiatryeducationforum.com/ Inside the Academy: • 500+ clinical chapters • Case-based discussions • Journal Club • Closed physician-only community 📌 Comment below: Where do you think Bysanti fits in your treatment algorithm for schizophrenia or bipolar mania?